Protein Therapeutics

Overview of Protein Therapies

Protein therapeutics are engineered proteins used in medicine to treat diseases, alleviate symptoms, or repair biological structures. These proteins are administered in precise amounts and are often produced using recombinant DNA technology.

• Definition: Therapeutic proteins are laboratory-engineered proteins for pharmaceutical use.

• Applications: Used to treat illnesses, pain, and structural repair.

• Production: Most are recombinant proteins, produced using genetic engineering.

Advantages and Disadvantages of Protein Therapies

Protein therapies offer several benefits over traditional small molecule drugs, but also present unique challenges.

• Advantages:

  • Highly specific and selective

  • Low toxicity and fewer side effects

  • Low tissue accumulation

  • High biological and chemical diversity

• Disadvantages:

  • Metabolic instability

  • Poor membrane permeability

  • Poor oral bioavailability

  • Poor solubility

  • Rapid clearance from the body

  • High manufacturing and quality assurance costs

Protein Engineering and Recombinant DNA Technology

Protein engineering involves modifying proteins to enhance their properties for therapeutic use. Recombinant DNA technology enables the production of these proteins in host cells.

• Protein Engineering: Altering protein structure/function for improved efficacy.

• Recombinant DNA Technology: Inserting genes encoding therapeutic proteins into host cells for expression.

Timeline of Protein Therapeutics Development

The development of protein therapeutics has evolved rapidly since the early 20th century, with milestones including the use of insulin, growth hormone, and monoclonal antibodies.

• 1920s: Insulin therapy introduced

• 1982: Recombinant human insulin approved

• 1985: Recombinant growth hormone manufactured

• 1997: First chimeric and humanized antibodies approved

• 1998: First fusion protein approved

Classification of Protein Therapies

Protein therapeutics are classified based on their mechanism and application:

• Group I: Enzymatic or regulatory activity

  • Ia: Replacement of deficient/abnormal protein

  • Ib: Augmentation of existing pathway

  • Ic: Provision of novel function/activity

• Group II: Special targeting activity

  • IIa: Interference with molecules/organisms

  • IIb: Delivery of compounds/proteins

• Group III: Protein vaccines

  • IIIa: Protection against foreign agents

  • IIIb: Treatment of autoimmune disease

  • IIIc: Cancer treatment

• Group IV: Protein diagnostics

Distribution and Complexity of Therapeutic Proteins

• Monoclonal antibodies constitute nearly half of approved protein therapies.

• Therapeutic proteins are used across diverse medical fields, including oncology, immunology, and endocrinology.

• Protein drugs are more complex and costly to manufacture than small molecule drugs.

Case Study: Alpha-1 Antitrypsin (Aralast/Prolastin)

Alpha-1 Antitrypsin Deficiency

Alpha-1 antitrypsin (AAT) is a protein that inhibits elastase, a protease active in lung tissue. Deficiency in AAT leads to lung and liver disease.

• Genetic Basis: Autosomal recessive disorder caused by mutations in the SERPINA1 gene.

• Clinical Manifestations:

  • Liver cirrhosis due to misfolded AAT trapped in the liver

  • Emphysema due to unregulated elastase activity in the lungs

• Therapeutic Approach: Replacement therapy with purified or recombinant AAT.

Alpha-1 Antitrypsin Therapy and Recombinant Fc-AAT

• Traditional Therapy: Plasma-derived AAT, expensive and risk of contamination.

• Recombinant Fc-AAT: Fusion protein with Fc region for improved stability and purification.

• Benefits: Higher potency, easier purification, reduced cost, improved patient outcomes.

Case Study: TNKase (Tenecteplase)

TNKase and the Fibrinolytic System

TNKase is a genetically engineered tissue plasminogen activator (tPA) used to dissolve blood clots, especially in acute myocardial infarction.

• Mechanism: Converts plasminogen to plasmin, which degrades fibrin in blood clots.

• Therapeutic Class: Group I, Ib: Augmenting an existing pathway.

• Production: Recombinant protein produced in CHO cells.

Structural Modifications of TNKase

TNKase is a modified version of alteplase with enhanced properties:

• T103N: Adds glycosylation site

• N117Q: Removes glycosylation site

• K296, H297, R298, R299: Replaced by alanine for enhanced fibrin specificity and resistance to PAI-1 inhibition

• Longer half-life and single-dose administration

Case Study: Pulmozyme (Dornase Alfa)

Pulmozyme and Cystic Fibrosis

Pulmozyme is a recombinant human deoxyribonuclease 1 (DNase I) used to treat cystic fibrosis by degrading extracellular DNA in pulmonary secretions.

• Mechanism: Hydrolyzes DNA in mucus, reducing viscosity and promoting clearance.

• Clinical Use: Reduces respiratory infections and improves lung function in cystic fibrosis patients.

• Production: Recombinant protein produced in CHO cells.

Cystic Fibrosis Pathophysiology

• Genetic Basis: Autosomal recessive mutations in the CFTR gene.

• Manifestations: Thick, viscous pulmonary secretions, frequent infections, reduced lung function.

• Common Mutations: G551D (defective channel), F508del (misfolded protein).

Pulmozyme Administration

• Administered as an aerosol mist via nebulizer.

• Thins pulmonary secretions, reduces infection risk, improves lung function.

Summary: Key Concepts in Protein Therapeutics

• Understanding the classification and mechanism of protein therapies

• Advantages and limitations compared to small molecule drugs

• Examples of protein therapies, including recombinant proteins and their modifications

• Pathophysiology of diseases treated by protein therapeutics

• Production and administration methods for therapeutic proteins

Additional info: Academic context was added to clarify mechanisms, genetic basis, and therapeutic approaches for each protein therapy example.